Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action

Experimental and Molecular Pathology

Volumn 81, Issue 2, 2006, Pages 136-145

  Sharma, Meena R ^c   Rothman, Vicki ^b   Tuszynski, George P ^b   Sharma, Mahesh C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Angiostatin; Annexin II; ECM; Invasion; Lewis Lung Carcinoma; Metastasis; Plasmin; Tumor growth

Indexed keywords

AMINOCAPROIC ACID; ANGIOSTATIN; ANNEXIN; ANTIBODY; ANTIPLASMIN; BLOCKING ANTIBODY; LIPOCORTIN 2; LYSINE; MONOCLONAL ANTIBODY; PLASMIN; PLASMINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL SURFACE; CONTROLLED STUDY; FEMALE; GENE CONTROL; KRINGLE DOMAIN; LEWIS CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN TARGETING; STATISTICAL MODEL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANNEXIN A2; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CATTLE; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; PLASMIN; PLASMINOGEN;

EID: 33750811184     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2006.03.002     Document Type: Article

References (45)

1. Aguilar S., Corominas J.M., Malats N., Pereira J.A., Dufresne M., Real F.X., and Navarro P. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am. J. Pathol. 165 (2004) 1129-1139
2. Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72 (1997) 1-22
3. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., Fusenig N.E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., Foidart J.M., and Noel A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152 (2001) 777-784
4. Banerjee A.G., Liu J., Yuan Y., Gopalakrishnan V.K., Johansson S.L., Dinda A.K., Gupta N.P., Trevino L., and Vishwanatha J.K. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol. Cancer 2 (2003) 34
5. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 15 (1993) 105-111
6. Blasi F., and Stoppelli M.P. Proteases and cancer invasion: from belief to certainty. Biochim. Biophys. Acta 1423 (1998) R35-R44
7. Brichory F., Beer D., Le Naour F., Giordano T., and Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61 (2001) 7908-7912
8. Brichory F.M., Misek D.E., Yim A.M., Krause M.C., Giordano T.J., Beer D.G., and Hanash S.M. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9824-9829
9. Brownstein C., Deora A.B., Jacovina A.T., Weintraub R., Gertler M., Khan K.M., Falcone D.J., and Hajjar K.A. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 103 (2004) 317-324
10. Bugge T.H., Kombrinck K.W., Xiao Q., Holmback K., Daugherty C.C., Witte D.P., and Degen J.L. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 90 (1997) 4522-4531
11. Cesarman G.M., Guevara C.A., and Hajjar K.A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA): II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269 (1994) 21198-21203
12. Diaz V.M., Hurtado M., Thomson T.M., Reventos J., and Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 53 (2004) 993-1000
13. Dudani A.K., and Ganz P.R. Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br. J. Haematol. 95 (1996) 168-178
14. Felez J., Miles L.A., Fabregas P., Jardi M., Plow E.F., and Lijnen R.H. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb. Haemost. 76 (1996) 577-584
15. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., Perricaudet M., Yeh P., and Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6367-6372
16. Hajjar K.A., Jacovina A.T., and Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator: I. Identity with annexin II. J. Biol. Chem. 269 (1994) 21191-21197
17. Kimura Y., Baba K., and Okuda H. Inhibitory effects of active substances isolated from Cassia garrettiana heartwood on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice (Part 1). Anticancer Res. 20 (2000) 2899-2906
18. Kobayashi H., Shinohara H., Fujie M., Gotoh J., Itoh M., Takeuchi K., and Terao T. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Int. J. Cancer 63 (1995) 455-462
19. Ling Q., Jacovina A.T., Deora A., Febbraio M., Simantov R., Silverstein R.L., Hempstead B., Mark W.H., and Hajjar K.A. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest. 113 (2004) 38-48
20. Liotta, L.A., 1992. Cancer cell invasion and metastasis. Sci. Am. 266 54-9, 62-3.
21. McColl B.K., Baldwin M.E., Roufail S., Freeman C., Moritz R.L., Simpson R.J., Alitalo K., Stacker S.A., and Achen M.G. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med. 198 (2003) 863-868
22. Mignatti P., and Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73 (1993) 161-195
23. Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L., Hubchak S., Schnaper H.W., and Pizzo S.V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2811-2816
24. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
25. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2 (1996) 689-692
26. Pepper M.S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86 (2001) 346-355
27. Pepper M.S., and Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. 32 (1990) 319-327
28. Pepper M.S., Montesano R., Mandriota S.J., Orci L., and Vassalli J.D. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49 (1996) 138-162
29. Peyruchaud O., Serre C.M., NicAmhlaoibh R., Fournier P., and Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J. Biol. Chem. 278 (2003) 45826-45832
30. Roseman B.J., Bollen A., Hsu J., Lamborn K., and Israel M.A. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol. Res. 6 (1994) 561-567
31. Semov A., Moreno M.J., Onichtchenko A., Abulrob A., Ball M., Ekiel I., Pietrzynski G., Stanimirovic D., and Alakhov V. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J. Biol. Chem. 280 (2005) 20833-20841
32. Sharma M.C., and Shapiro B.H. Purification and characterization of constituent testosterone 2 alpha-hydroxylase (cytochrome P450(2)alpha) from mouse liver. Arch. Biochem. Biophys. 316 (1995) 478-484
33. Sharma M.C., and Tuszynski G.P. Methods and Composition for Inhibiting Angiogenesis (2002), World Intellectual Property Organization A3 WO:02/17857
34. Sharma M.R., Tuszynski G.P., and Sharma M.C. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J. Cell. Biochem. 91 (2004) 398-409
35. Sim B.K., O'Reilly M.S., Liang H., Fortier A.H., He W., Madsen J.W., Lapcevich R., and Nacy C.A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57 (1997) 1329-1334
36. Stephens R.W., Nielsen H.J., Christensen I.J., Thorlacius-Ussing O., Sorensen S., Dano K., and Brunner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl. Cancer Inst. 91 (1999) 869-874
37. Tanaka N., Ogawa H., Kinjo M., Kohga S., and Tanaka K. Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma. Br. J. Cancer 46 (1982) 428-435
38. Tarui T., Miles L.A., and Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J. Biol. Chem. 276 (2001) 39562-39568
39. Tarui T., Majumdar M., Miles L.A., Ruf W., and Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J. Biol. Chem. 277 (2002) 33564-33570
40. Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., and Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 152 (2001) 1247-1254
41. Tuszynski G.P., Sharma M., Rothman V.L., and Sharma M.C. Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc. Res. 64 (2002) 448-462
42. Wu Z., O'Reilly M.S., Folkman J., and Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun. 236 (1997) 651-654
43. Wu W., Tang X., Hu W., Lotan R., Hong W.K., and Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin. Exp. Metastasis 19 (2002) 319-326
44. Zhou J., Rothman V.L., Sargiannidou I., Dimitrov S., Qiu C., Smith E., Sheffield J., Sharma M., and Tuszynski G.P. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J. Cell. Biochem. 92 (2004) 125-146
45. Zimmermann U., Woenckhaus C., Pietschmann S., Junker H., Maile S., Schultz K., Protzel C., and Giebel J. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch. 445 (2004) 368-374